← Russell 3000 cross-section

LNTH Lantheus Holdings, Inc.

Trailing twelve months to 2026-06-30 · as filed 2026-08-06, not restated
Healthcare

Scale

Market cap
$6.6bn
Revenue TTM
$1.6bn
Net income TTM
$275m
Free cash flow
Composite score
63.1
Sector rank
#916

Valuation

P / E
23.9
EV / EBITDA
15.3
EV / sales
3.9
FCF yield
Earnings yield vs 10-yr
-0.55pp

Earnings yield vs 10-yr compares what the business earns per pound invested against the 4.73% a 10-year US Treasury note pays for no equity risk. Negative means you are paying up front for growth not yet delivered.

Quality and growth

Net margin
17.7%
EBITDA margin
25.1%
ROE
21.0%
ROIC
42.1%
Revenue growth
2.4%

Insider activity, last 90 days

Net open-market
$0.00m
Buyers
0
Sellers
0

Open-market purchases and sales only. Grants, option exercises, gifts and shares withheld for tax are excluded: they are how people are paid, not what they think.

What management said

Following our sale of our SPECT business on January 1, 2026, we classify our revenues into four product categories: Oncology, Neurology, Cardiology, and Strategic Partnerships and Other Revenue, reflecting the evolution of our commercial portfolio and strategic focus. We have presented the prior year numbers for revenues to conform with our current year presentation, including the disaggregation of revenue related to the single-photon emission computerized tomography (“SPECT”) business which was divested to SHINE Technologies, LLC (“SHINE”), a wholly-owned subsidiary of Illuminated Holdings, Inc. …Lantheus Holdings, Inc., 10-Q, period ended 2026-06-30, filed 2026-08-06

Read the full passage →